Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial

Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine

Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections

This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company

GSK names Luke Miels as next CEO

Miels will formally assume the role on January 1, 2026

FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia

FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses

Revvity launches AI-powered software to transform preclinical imaging analysis

The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities

Aptar Pharma opens new R&D center in France

Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Lupin acquires VISUfarma to strengthen specialty ophthalmology portfolio

The Lancet Regional Health publishes pivotal phase 3 clinical study on Miqnaf

DMMA warns regulatory burden threatening Gujarat’s pharma MSMEs

The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.